Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform - 01/02/22
Doi : 10.1016/S1470-2045(21)00707-5
Laurien J Zeverijn a, c, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani d, Anke A M G Pisters van Roy d, Lonneke Timmers e, T H Ly Tran e, Jolanda E de Boer e, Gijsbrecht F de Wit a, c, Birgit S Geurts a, c, Hans Gelderblom f, Henk M W Verheul h, Nicole Blijlevens i, A N Machteld Wymenga j, Ferry A L M Eskens k, Egbert F Smit b, g, Haiko J Bloemendal h, Emile E Voest a, c 
a Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands
b Department of Thoracic Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands
c Oncode Institute, Utrecht, Netherlands
d CZ Health Insurance, Tilburg, Netherlands
e National Health Care Institute (Zorginstituut Nederland), Diemen, Netherlands
f Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands
g Department of Pulmonary Diseases, Leiden University Medical Center, Leiden, Netherlands
h Department of Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands
i Department of Hematology, Radboud University Medical Center, Nijmegen, Netherlands
j Department of Medical Oncology, Medical Spectrum Twente, Enschede, Netherlands
k Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
El texto completo de este artículo está disponible en PDF.
© 2022
Elsevier Ltd. Reservados todos los derechos.© 2022
EM Karuna/Shutterstock.com. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Vol 23 - N° 2
P. 198-201 - février 2022 Regresar al número
Artículo precedente
- Japan resumes active recommendations of HPV vaccine after 8·5 years of suspension
- Rei Haruyama, Hiromi Obara, Noriko Fujita
- Global consequences of the US FDA’s accelerated approval of cancer drugs
- Amol Akhade, Bhawna Sirohi, Bishal Gyawali
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?